Cargando…
In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker
Protein citrullination and degradation by matrix metalloproteinases (MMP) plays a central role in the pathology of rheumatoid arthritis (RA). Autoantibodies are known to target citrullinated vimentin. The aim of this study was to investigate the relationship between the blood levels of MMP-degraded...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820189/ https://www.ncbi.nlm.nih.gov/pubmed/36613765 http://dx.doi.org/10.3390/ijms24010321 |
_version_ | 1784865408196542464 |
---|---|
author | Drobinski, Patryk J. Nissen, Neel I. Sinkeviciute, Dovile Willumsen, Nicholas Karsdal, Morten A. Bay-Jensen, Anne C. |
author_facet | Drobinski, Patryk J. Nissen, Neel I. Sinkeviciute, Dovile Willumsen, Nicholas Karsdal, Morten A. Bay-Jensen, Anne C. |
author_sort | Drobinski, Patryk J. |
collection | PubMed |
description | Protein citrullination and degradation by matrix metalloproteinases (MMP) plays a central role in the pathology of rheumatoid arthritis (RA). Autoantibodies are known to target citrullinated vimentin. The aim of this study was to investigate the relationship between the blood levels of MMP-degraded and citrullinated vimentin (VICM), as compared with the levels of MMP-degraded and non-citrullinated vimentin (VIM), and the standard anti-CCP biomarker in RA patients undergoing treatment. Thus, VIM, VICM and anti-CCP were quantified by ELISA in serum samples from baseline and week 8 of patients (n = 257) with RA, treated with either tocilizumab (8 mg/kg), methotrexate (7.5–15 mg/kg) or a placebo and compared with a reference cohort (n = 64). The three biomarkers were elevated in RA serum compared with the reference cohort: medians were 1.7 vs. 0.8 ng/mL (p < 0.05) for VIM; 7.5 vs. 0.7 ng/mL (p < 0.0001) for VICM; 57 vs. 4 RU/mL (p < 0.001) for anti-CCP. VICM was decreased in response to tocilizumab (2.9-fold, p < 0.0001) and to methotrexate (1.5-fold, p < 0.05) compared with the placebo, while anti-CCP was not. Serum VIM was also modulated by both drugs, although to a lesser degree. A high baseline level of VICM was predictive of a low disease activity response at week 8. In conclusion, VICM can differentiate between RA and healthy donors in a similar manner to anti-CCP; furthermore, VICM is also a pharmacodynamic marker. |
format | Online Article Text |
id | pubmed-9820189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98201892023-01-07 In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker Drobinski, Patryk J. Nissen, Neel I. Sinkeviciute, Dovile Willumsen, Nicholas Karsdal, Morten A. Bay-Jensen, Anne C. Int J Mol Sci Article Protein citrullination and degradation by matrix metalloproteinases (MMP) plays a central role in the pathology of rheumatoid arthritis (RA). Autoantibodies are known to target citrullinated vimentin. The aim of this study was to investigate the relationship between the blood levels of MMP-degraded and citrullinated vimentin (VICM), as compared with the levels of MMP-degraded and non-citrullinated vimentin (VIM), and the standard anti-CCP biomarker in RA patients undergoing treatment. Thus, VIM, VICM and anti-CCP were quantified by ELISA in serum samples from baseline and week 8 of patients (n = 257) with RA, treated with either tocilizumab (8 mg/kg), methotrexate (7.5–15 mg/kg) or a placebo and compared with a reference cohort (n = 64). The three biomarkers were elevated in RA serum compared with the reference cohort: medians were 1.7 vs. 0.8 ng/mL (p < 0.05) for VIM; 7.5 vs. 0.7 ng/mL (p < 0.0001) for VICM; 57 vs. 4 RU/mL (p < 0.001) for anti-CCP. VICM was decreased in response to tocilizumab (2.9-fold, p < 0.0001) and to methotrexate (1.5-fold, p < 0.05) compared with the placebo, while anti-CCP was not. Serum VIM was also modulated by both drugs, although to a lesser degree. A high baseline level of VICM was predictive of a low disease activity response at week 8. In conclusion, VICM can differentiate between RA and healthy donors in a similar manner to anti-CCP; furthermore, VICM is also a pharmacodynamic marker. MDPI 2022-12-24 /pmc/articles/PMC9820189/ /pubmed/36613765 http://dx.doi.org/10.3390/ijms24010321 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Drobinski, Patryk J. Nissen, Neel I. Sinkeviciute, Dovile Willumsen, Nicholas Karsdal, Morten A. Bay-Jensen, Anne C. In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker |
title | In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker |
title_full | In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker |
title_fullStr | In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker |
title_full_unstemmed | In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker |
title_short | In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker |
title_sort | in contrast to anti-ccp, mmp-degraded and citrullinated vimentin (vicm) is both a diagnostic and a treatment response biomarker |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820189/ https://www.ncbi.nlm.nih.gov/pubmed/36613765 http://dx.doi.org/10.3390/ijms24010321 |
work_keys_str_mv | AT drobinskipatrykj incontrasttoanticcpmmpdegradedandcitrullinatedvimentinvicmisbothadiagnosticandatreatmentresponsebiomarker AT nissenneeli incontrasttoanticcpmmpdegradedandcitrullinatedvimentinvicmisbothadiagnosticandatreatmentresponsebiomarker AT sinkeviciutedovile incontrasttoanticcpmmpdegradedandcitrullinatedvimentinvicmisbothadiagnosticandatreatmentresponsebiomarker AT willumsennicholas incontrasttoanticcpmmpdegradedandcitrullinatedvimentinvicmisbothadiagnosticandatreatmentresponsebiomarker AT karsdalmortena incontrasttoanticcpmmpdegradedandcitrullinatedvimentinvicmisbothadiagnosticandatreatmentresponsebiomarker AT bayjensenannec incontrasttoanticcpmmpdegradedandcitrullinatedvimentinvicmisbothadiagnosticandatreatmentresponsebiomarker |